Atlantic Health System and Atlantic Center for Research Deliver New Chapter in Bladder Cancer Care
Dr. Sandip Prasad leads an international trial that brings new bladder-sparing therapy to patients
Clinical Scorecard: Atlantic Health System and Atlantic Center for Research Deliver New Chapter in Bladder Cancer Care
At a Glance
| Category | Detail |
|---|
| Condition | Non-Muscle Invasive Bladder Cancer (NMIBC) |
| Key Mechanisms | Reverse thermal gel containing mitomycin, administered via catheter. |
| Target Population | Patients with low-grade, intermediate-risk NMIBC. |
| Care Setting | Outpatient, office-based treatment. |
Key Highlights
- FDA approval of Zusduri™ (mitomycin) for NMIBC.
- Most patients in the ENVISION trial achieved a complete response.
- Non-surgical treatment option that preserves quality of life.
- Atlantic Health System was a top-enrolling site for the ENVISION trial.
- Collaboration between Urology and Oncology specialists enhances patient care.
Guideline-Based Recommendations
Diagnosis
- Utilize clinical trials to evaluate novel treatments for NMIBC.
Management
- Consider Zusduri™ as a first-line treatment for eligible patients.
Monitoring & Follow-up
- Regular follow-up to assess treatment response and disease status.
Risks
- Potential for recurrence of bladder cancer despite treatment.
Patient & Prescribing Data
Patients with recurring, low-grade NMIBC.
Zusduri™ offers a non-surgical alternative with a favorable response rate.
Clinical Best Practices
- Implement multidisciplinary care plans tailored to individual patient needs.
- Encourage participation in clinical trials for access to innovative therapies.
- Maintain close coordination between urology and oncology teams.
References
